iDexis Semaglutide Ban Ordered By High Court
iDexis semaglutide ban stops the pharmacy group from selling compounded weight-loss medicines while SAHPRA and the SAPC investigate.
Semaglutide Compounding Dispute: Novo Nordisk Heads To Court
The Semaglutide Compounding Dispute intensifies as Novo Nordisk takes iDexis to court over illegal manufacturing of weight-loss injections.
Compounded GLP-1 Injections Spark Regulatory Battle
Compounded GLP-1 injections are at the centre of a regulatory dispute. iDexis challenges SAHPRA and SAPC recall orders.